Forget Vertex Pharmaceuticals; CRISPR Therapeutics Is a Better Biotech Growth Stock
Both CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are biotech stocks that have plenty of positive things going for them. In fact, these companies happen to be partners in an ongoing project to treat genetic diseases via gene-editing technologies. Yet despite this commonality, these stocks are radically different from one another, and each has its own unique upside potential.
While the much larger and better-established Vertex might seem like a strong pick, especially considering its long-term pipeline of preclinical and clinical treatments, I'd argue that its growth potential isn't as promising as that of CRISPR. Below, I'll explain exactly why, if I had to pick, I'd buy shares of CRISPR before Vertex.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
